Greatbatch (NYSE:GB) said today that it’s planning to shuffle its manufacturing operation, moving some production from Minnesota, Oregon and Massachusetts to plants in Tijuana, Mexico.
integer
Greatbatch requests CE Mark for spinal cord stim
Greatbatch (NYSE:GB) filed a CE Mark application for its spinal cord stimulation system with German notified body TÜV SÜD America.
Greatbatch submits PMA for spinal cord stim
Greatbatch (NYSE:GB) this week filed a pre-market approval application with the FDA for its spinal cord neuromodulation system.
The neuromodulation system comes from the Frisco, Texas-based company’s subsidiary, QiG Group, which hopes to win indication to treat chronic pain of the trunk and limbs.
Greatbatch gains on Q3 swing to black, earnings beat
Greatbatch (NYSE:GB) shares are up this morning after the medical device company reported a profitable 3rd quarter and beat Wall Street’s expectations for per-share earnings.
Uroplasty’s new CFO hails from Synovis | Personnel Moves
Greatbatch raises guidance on Q2 figures
Texas medical device maker Greatbatch (NYSE:GB) posted a profit in Q2 and nudged its 2013 per-share earnings guidance up for the 2nd time in 2 months. The device maker’s Q2’s sales eked out a 3% boost over last year’s figures and profits were up 10%, according to the financial release.
Greatbatch raises 2013 guidance on restructuring efforts | Wall Street Beat
Texas medical device maker Greatbatch (NYSE:GB) raised its 2013 per-share earnings guidance as it announced new efforts to reorganize some of its business practices and reduce costs as it shifts from a components and sub-assemblies company to a developer of full medical devices.
Edwards CEO Mussallem details U.S. Sapien sales guidance, updates on CoreValve case | Wall Street Beat
Edwards Lifesciences (NYSE:EW) chairman & CEO Michael Mussallem said the medical device company expects to post U.S. sales of $390 million-$440 million for its flagship Sapien heart valve, adding 200 new sites over the next 2 years to its existing roster of 200 sites.
AngioDynamics names senior VP & CTO | Personnel Moves
Greatbatch slips to loss in Q3 with Swiss plant closure costs
Medical device maker Greatbatch (NYSE:GB) lost $7.6 million in 3Q, the result of the nearly $15 million in expense to close a pair of Swiss factories.
Sunshine Heart soars on C-Pulse CE Mark | Wall Street Beat
Sunshine Heart (ASX:SHC) is shining on Wall Street today after announcing European regulatory approval for its C-Pulse heart assist system, with SHC shares closing up nearly 14% on the news.